Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “ras”

843 pharma patents match "ras" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 843
Index total 30,257
Page 22 / 36

Quick answer

This filtered view shows 843 pharmaceutical patents matching "ras" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

843 results for “ras” · 30,257 patents in full index Clear search

  1. US 8722616

    Anti-HIV peptides and methods of use thereof

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted May 13, 2014 · Expires May 8, 2034

    granted

  2. US 8722884

    Pyrimidine derivatives for the treatment of abnormal cell growth

    VERASTEM, INC. · Granted May 13, 2014 · Expires May 8, 2034

    granted

  3. US 8709995

    Method for eliciting an immune response to human telomerase reverse transcriptase

    The Regents of the University of Colorado · Granted Apr 29, 2014 · Expires Apr 24, 2034

    granted

  4. US 8697836

    Composition and method for inducing and enhancing a telomerase reverse transcriptase-reactive cytotoxic T lymphocyte response

    The Regents of the University of California · Granted Apr 15, 2014 · Expires Apr 10, 2034

    granted

  5. US 8691501

    Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Apr 8, 2014 · Expires Apr 3, 2034

    granted

  6. US 8691872

    Dispersions of rasagiline citrate

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Apr 8, 2014 · Expires Apr 3, 2034

    granted

  7. US 8686041

    Inhibition of ornithine aminotransferase for the treatment of proliferative disorders

    Northwestern University · Granted Apr 1, 2014 · Expires Mar 27, 2034

    granted

  8. US 8680046

    Inhibitors of viral integrase and methods of use

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Mar 25, 2014 · Expires Mar 20, 2034

    granted

  9. US 8673316

    Avirulent, immunogenic flavivirus chimeras

    THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION · Granted Mar 18, 2014 · Expires Mar 13, 2034

    granted

  10. US 8669249

    Poly (ADP-ribose) polymerase (PARP) inhibitors

    Takeda Pharmaceutical Company Limited · Granted Mar 11, 2014 · Expires Mar 6, 2034

    granted

  11. CA 2881745

    COMPOSITIONS OPHTALMIQUES CONTENANT DES ACIDES GRAS OMEGA -3

    BAUSCH & LOMB [US] · Granted Mar 6, 2014 · Expires Mar 1, 2034

    granted

  12. US 8614252

    Crystalline solid rasagiline base

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Dec 24, 2013 · Expires Dec 19, 2033

    granted

  13. US 8614301

    Methods of treating cancer using anti CD24 antibodies

    The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center · Granted Dec 24, 2013 · Expires Dec 19, 2033

    granted

  14. US 8609838

    Pyrimidine substituted purine derivatives

    VERASTEM, INC. · Granted Dec 17, 2013 · Expires Dec 12, 2033

    granted

  15. US 8598322

    Anti CEACAM1 antibodies and methods of using same

    TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted

  16. US 8597655

    Recombinant fusion protein and polynucleotide construct for immunotoxin production

    The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted

  17. US 8592464

    Nitric oxide furoxan derivative compounds endowed with antitumoral activity

    HUMANITAS MIRASOLE S.P.A. · Granted Nov 26, 2013 · Expires Nov 21, 2033

    granted

  18. US 8580822

    Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors

    REVIVA PHARMACEUTICALS, INC. · Granted Nov 12, 2013 · Expires Nov 7, 2033

    granted

  19. US 8580231

    Compositions and methods comprising magnetic resonance contrast agents

    Northwestern University · Granted Nov 12, 2013 · Expires Nov 7, 2033

    granted

  20. US 8575167

    Spiro compounds having stearoyl-CoA desaturase action

    Takeda Pharmaceutical Company Limited · Granted Nov 5, 2013 · Expires Oct 31, 2033

    granted

  21. US 8569379

    Use of rasagiline for the treatment of olfactory dysfunction

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Oct 29, 2013 · Expires Oct 24, 2033

    granted

  22. US 8552147

    Peptides and compositions for prevention of cell adhesion and methods of using same

    TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. · Granted Oct 8, 2013 · Expires Oct 3, 2033

    granted

  23. US 8545813

    Pre-templated macromolecular architectures with multiple Gd(III) complexes and methods of use as MRI contrast agents

    Northwestern University · Granted Oct 1, 2013 · Expires Sep 26, 2033

    granted

  24. US 8541417

    Poly (ADP-ribose) polymerase (PARP) inhibitors

    Takeda Pharmaceutical Company Limited · Granted Sep 24, 2013 · Expires Sep 19, 2033

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.